CN102415992A - Escitalopram oral liquid preparation - Google Patents
Escitalopram oral liquid preparation Download PDFInfo
- Publication number
- CN102415992A CN102415992A CN2011103781324A CN201110378132A CN102415992A CN 102415992 A CN102415992 A CN 102415992A CN 2011103781324 A CN2011103781324 A CN 2011103781324A CN 201110378132 A CN201110378132 A CN 201110378132A CN 102415992 A CN102415992 A CN 102415992A
- Authority
- CN
- China
- Prior art keywords
- escitalopram
- oral liquid
- antiseptic
- glycerol
- sodium citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title claims abstract description 47
- 229960004341 escitalopram Drugs 0.000 title claims abstract description 47
- 239000007788 liquid Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 239000001509 sodium citrate Substances 0.000 claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 51
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 230000002421 anti-septic effect Effects 0.000 claims description 11
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 10
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 9
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 229960003415 propylparaben Drugs 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 4
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 abstract description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 2
- 235000003599 food sweetener Nutrition 0.000 abstract description 2
- 239000003765 sweetening agent Substances 0.000 abstract description 2
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940048396 escitalopram 5 mg Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses an escitalopram oral liquid preparation, which comprises effective dose of escitalopram and a pH regulator, wherein the pH value of the liquid is 4.0-5.2, an acidic buffering agent of malic acid-sodium citrate and citric acid-sodium citrate is preferably used as the pH regulator, and the escitalopram oral liquid preparation also comprises a sweetening agent and a preservative. The oral liquid preparation has good stability, and the escitalopram is not easy to degrade in water, and has good taste and good compliance for taking medicine.
Description
Technical field
The present invention relates to the escitalopram preparation, be specifically related to a kind of escitalopram oral liquid.
Background technology
The chemical name of escitalopram: (+)-1S-[3-(dimethylamino) propyl group]-1-(4-fluorophenyl)-1, the different phenylpropyl alcohol furan of 3-dihydro-5-nitrile oxalates, its structural formula is:
Molecular formula: C
20H
21FN
2OC
2H
2O
4
Molecular weight: 414.43
Escitalopram is mainly used in the treatment of depression clinically, has only tablet listing at present at home, because these article hydrolytically unstable and bitter in the mouth in liquid have easily limited its application in oral liquid.
Summary of the invention
The object of the present invention is to provide a kind of good stability, escitalopram oral liquid that mouthfeel is good.
The present invention realizes through following technical scheme:
A kind of oral liquid comprises the escitalopram of effective dose, it is characterized in that also comprising the PH regulator, and the pH value of said oral liquid is 4.0-5.2.
The preferred pH value of the present invention is 4.6.
Said PH regulator is acidic materials such as pharmaceutically useful hydrochloric acid, acetic acid, oxalic acid, phosphoric acid, malic acid, citric acid, acid buffer agent.
The preferred PH regulator of the present invention is an acid buffer agent.
Further, acid buffer agent preferred mass ratio of the present invention is citric acid and the sodium citrate that 6: 7 malic acid and sodium citrate or mass ratio is 1: 2.
Oral liquid of the present invention also comprises at least a pharmaceutically useful sweeting agent, like sucrose, glucose, fructose, maltose, lactose, mannitol, sorbitol, glycerol, propylene glycol and glucide, aspartame, acesulfame potassium, sucralose etc.
Preferred sweeteners of the present invention comprises at least a in glycerol, the propylene glycol.Like independent employing glycerol or propylene glycol as sweeting agent; Perhaps make up glycerol and sucrose as sweeting agent; Perhaps make up glycerol and aspartame as sweeting agent, perhaps make up glycerol and sucrose, maltose as sweeting agent, perhaps make up propylene glycol and mannitol as sweeting agent; Perhaps propylene glycol and glycerol, sorbitol combination as sweeting agent etc., as long as contain glycerol and/or propylene glycol in the sweeting agent.
Glycerol and/or propylene glycol are that concentration with 100-550ml/L exists in the above-mentioned sweeting agent.
Oral liquid of the present invention also comprises at least a antiseptic, and said antiseptic is selected from methyl hydroxybenzoate, ethyl hydroxybenzoate, propylparaben, butoben, sodium benzoate.
Said antiseptic is that the concentration with 0.9-4.4g/L exists.
During preparation, escitalopram, PH regulator, antiseptic, sweeting agent are dissolved in the water by concentration requirement, stir and make dissolving and mix homogeneously fully, filter, embedding, sterilization promptly get.In order to make oral liquid mouthfeel of the present invention better, can also add an amount of aromatic, like Herba Menthae essence, Fructus Citri Limoniae essence, flavoring orange essence etc.
Beneficial effect of the present invention has:
(1) the pH stabilizing agent among the present invention can reduce the hydrolysis rate of escitalopram in liquid, and escitalopram can be degraded before the deadline, thereby guarantees the curative effect of medicine, prolongs the effect duration of product;
(2) adopt sweeting agent of the present invention, can cover the bitterness of escitalopram, improve the mouthfeel of preparation, improve the compliance of taking medicine;
(3) glycerol, propylene glycol are not only a kind of sweeting agent, also are cosolvent (cosolvent) and thickening agent simultaneously, and the effect that improves the preparation mouthfeel is not only arranged, and the dissolubility of the escitalopram of raising in water also arranged simultaneously and make the more stable effect of liquid preparation.Therefore multiple effect has been played in glycerol, propylene glycol use in the present invention, has obtained unexpected technique effect.
(4) use of antiseptic can make oral liquid of the present invention should not grow antibacterial, guarantees drug safety.
The specific embodiment
Embodiment 1
A kind of escitalopram oral liquid, contain following composition:
Method for preparing is: ethyl hydroxybenzoate is dissolved in an amount of glycerol, escitalopram, citric acid are dissolved in the suitable quantity of water, be stirred to dissolving fully; Add the glycerite of ethyl hydroxybenzoate, stir, add the glycerol of surplus; Add Herba Menthae essence, add water to 1000ml, mix homogeneously; Filter, embedding, sterilization promptly get.
Escitalopram oral liquid pH value of the present invention is 4.6.
The taking dose of escitalopram oral liquid of the present invention is each oral 5ml, contains escitalopram 5mg, and take 2-3 every day.
Embodiment 2
A kind of escitalopram oral liquid, contain following composition:
Method for preparing is: methyl hydroxybenzoate, propylparaben are dissolved in the propylene glycol, with escitalopram, citric acid, sodium citrate, add an amount of water stirring and dissolving; Add the propylene glycol solution of sorbitol and methyl hydroxybenzoate, propylparaben, stir, add flavoring orange essence; Add water to 1000ml; Stir, filter, embedding, sterilization promptly get.
Escitalopram oral liquid pH value of the present invention is 4.6.
Embodiment 3
A kind of escitalopram oral liquid, contain following composition:
Method for preparing is: ethyl hydroxybenzoate, butoben are dissolved in the propylene glycol, escitalopram, malic acid, sodium citrate are added stirring and dissolving in an amount of water, add the propylene glycol solution of glycerol and ethyl hydroxybenzoate, butoben; Stir; Add Fructus Citri Limoniae essence, add water to 1000ml, stir; Filter, embedding, sterilization promptly get.
Escitalopram oral liquid pH value of the present invention is 4.6.
Embodiment 4
A kind of escitalopram oral liquid, contain following composition:
Method for preparing is: ethyl hydroxybenzoate is dissolved in the glycerol, with escitalopram, malic acid, sodium citrate, sodium benzoate, adds an amount of water stirring and dissolving; Add the glycerite of sorbitol, ethyl hydroxybenzoate, stir, add Herba Menthae essence; Add water to 1000ml; Stir, filter, embedding, sterilization promptly get.
Escitalopram oral liquid pH value of the present invention is 4.6.
Embodiment 5
The screening test of PH regulator
(1) the 0.1g escitalopram is dissolved in 100ml water, gets Test Example 1
(2) respectively the 0.1g escitalopram is dissolved in 100ml water, regulates pH value to 3.6,4.0,4.5,5.2,5.5, get Test Example 2-6 with 0.1M hydrochloric acid;
(3) respectively the 0.1g escitalopram is dissolved in 100ml water, regulates pH value to 3.6,4.0,4.5,5.2,5.5, get Test Example 7-11 with citric acid;
(4) respectively the 0.1g escitalopram is dissolved in 100ml water, regulates pH value to 3.6,4.0,4.5,5.2,5.5, get Test Example 12-16 with malic acid-sodium citrate (6: 7) buffer agent;
(5) respectively the 0.1g escitalopram is dissolved in 100ml water, regulates pH value to 3.6,4.0,4.5,5.2,5.5, get Test Example 17-21 with citric acid-sodium citrate (1: 2) buffer agent.
(6) with above-mentioned 21 Test Example samples 60 ℃ hot environment held 10 days, surveyed pH value, content and related substance, result such as following table respectively at 0 day and 10 days:
Can find out from last table; The pH value of liquid preparation is on the rise; The content of escitalopram has the trend of reduction, and the content of related substance has the trend of increase, after adding the PH regulator; Above-mentioned trend is all slowed down to some extent, and the effect that wherein adds malic acid-sodium citrate (6: 7), citric acid-sodium citrate (1: 2) buffer agent obviously is superior to hydrochloric acid.Simultaneously can find out that also pH value solution when 4.0-5.2 is the most stable.
Claims (9)
1. escitalopram oral liquid is characterized in that comprising the escitalopram and the PH regulator of effective dose, and the pH value of said escitalopram oral liquid is 4.0-5.2.
2. escitalopram oral liquid as claimed in claim 1 is characterized in that pH value is 4.6.
3. according to claim 1 or claim 2 escitalopram oral liquid is characterized in that said PH regulator is an acid buffer agent.
4. escitalopram oral liquid as claimed in claim 3 is characterized in that said acid buffer agent is that mass ratio is citric acid and the sodium citrate that 6: 7 malic acid and sodium citrate or mass ratio is 1: 2.
5. according to claim 1 or claim 2 escitalopram oral liquid is characterized in that also comprising at least a pharmaceutically useful sweeting agent.
6. escitalopram oral liquid as claimed in claim 5 is characterized in that said sweeting agent comprises at least a in glycerol, the propylene glycol.
7. escitalopram oral liquid as claimed in claim 6 is characterized in that said glycerol and/or propylene glycol are that concentration with 100-550ml/L exists.
8. according to claim 1 or claim 2 escitalopram oral liquid; It is characterized in that also comprising antiseptic; Said antiseptic is one or more combination of methyl hydroxybenzoate, ethyl hydroxybenzoate, propylparaben, butoben, sodium benzoate, and said antiseptic is that the concentration with 0.9-4.4g/L exists.
9. escitalopram oral liquid as claimed in claim 5; It is characterized in that also comprising antiseptic; Said antiseptic is one or more combination of methyl hydroxybenzoate, ethyl hydroxybenzoate, propylparaben, butoben, sodium benzoate, and said antiseptic is that the concentration with 0.9-4.4g/L exists.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103781324A CN102415992A (en) | 2011-11-24 | 2011-11-24 | Escitalopram oral liquid preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103781324A CN102415992A (en) | 2011-11-24 | 2011-11-24 | Escitalopram oral liquid preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102415992A true CN102415992A (en) | 2012-04-18 |
Family
ID=45940796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103781324A Pending CN102415992A (en) | 2011-11-24 | 2011-11-24 | Escitalopram oral liquid preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102415992A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491521A (en) * | 2016-09-22 | 2017-03-15 | 北京万全德众医药生物技术有限公司 | A kind of oral liquor of escitalopram oxalate |
| CN110787304A (en) * | 2018-08-02 | 2020-02-14 | 北京万全德众医药生物技术有限公司 | Preparation method of escitalopram oxalate clathrate oral liquid |
| KR20200119021A (en) * | 2019-04-09 | 2020-10-19 | 주식회사 라이트팜텍 | Oral solution composition containing escitalopram with good stability and the method for preparing the same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1726298A2 (en) * | 2005-05-05 | 2006-11-29 | Errekappa Euroterapici S.p.A. | Oral liquid formulations containing citalopram |
| CN1911207A (en) * | 2006-09-08 | 2007-02-14 | 上海实业联合集团长城药业有限公司 | Oral liquor contg. citalopram hydrobromide and its prepn. method |
| CN101313903A (en) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | Medicament composition containing escitalopram |
-
2011
- 2011-11-24 CN CN2011103781324A patent/CN102415992A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1726298A2 (en) * | 2005-05-05 | 2006-11-29 | Errekappa Euroterapici S.p.A. | Oral liquid formulations containing citalopram |
| CN1911207A (en) * | 2006-09-08 | 2007-02-14 | 上海实业联合集团长城药业有限公司 | Oral liquor contg. citalopram hydrobromide and its prepn. method |
| CN101313903A (en) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | Medicament composition containing escitalopram |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491521A (en) * | 2016-09-22 | 2017-03-15 | 北京万全德众医药生物技术有限公司 | A kind of oral liquor of escitalopram oxalate |
| CN110787304A (en) * | 2018-08-02 | 2020-02-14 | 北京万全德众医药生物技术有限公司 | Preparation method of escitalopram oxalate clathrate oral liquid |
| KR20200119021A (en) * | 2019-04-09 | 2020-10-19 | 주식회사 라이트팜텍 | Oral solution composition containing escitalopram with good stability and the method for preparing the same |
| KR102331187B1 (en) * | 2019-04-09 | 2021-11-26 | 주식회사 라이트팜텍 | Oral solution composition containing escitalopram with good stability and the method for preparing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4445590B2 (en) | Oral liquid composition containing paroxetine-resin | |
| JP2016503762A5 (en) | ||
| TW200922579A (en) | Antimicrobial parenteral formulation | |
| CN102415992A (en) | Escitalopram oral liquid preparation | |
| WO2005004874A1 (en) | Stable tetrodotoxin freeze drying medicinal preparation | |
| CN102860980A (en) | Method for preparing rocuronium bromide injection | |
| CN1867359B (en) | Methylphenidate solution and its pharmaceutical uses and production | |
| TW201542240A (en) | Liquid pharmaceutical composition for oral administration comprising FEXOFENADINE | |
| EP2934593B1 (en) | Cabazitaxel composition | |
| CN103845295A (en) | Palonosetron preparation for injection and preparation method thereof | |
| CN103830240B (en) | A kind of flouroquinolone drugs compositions | |
| CN118304258A (en) | Escitalopram oral liquid preparation | |
| CN1867325A (en) | Jelly pharmaceutical preparation containing biguanide-based medicine | |
| ES2985944T3 (en) | Method for preparing a low-odor dicolinium ellagic acid salt and other low-odor organic choline salts | |
| CN102370656A (en) | Clarithromycin medicine composition and preparation method thereof | |
| TW201004656A (en) | A stable fluid composition of taxane derivatives, preparing method and use thereof | |
| CN101972257B (en) | A kind of pharmaceutical composition containing Moxifloxacin | |
| JP2010516717A (en) | Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer | |
| TW201008599A (en) | Formulations of canfosfamide and their preparation | |
| CN107510650B (en) | Pidotimod oral solution and preparation method thereof | |
| CN105412019A (en) | Soluble enrofloxacin powder and preparation method thereof | |
| JP2007008871A (en) | Percutaneous absorption promoting composition | |
| JP4136340B2 (en) | Injection | |
| CN109010276A (en) | A kind of preparation method of amoxicillin lipidosome sustained release agent | |
| RU2751351C2 (en) | Oral ibuprofen medication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 430056, No. three, No. 9, Maple Road, Wuhan economic and Technological Development Zone, Hubei, Wuhan Applicant after: Ferguson (Wuhan) Biological Technology Co., Ltd. Address before: 430056, building 8, hi tech Industrial Park, Wuhan economic and Technological Development Zone, Wuhan, Hubei Applicant before: Ferguson (Wuhan) Biological Technology Co., Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120418 |